

Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (cancelled).

Claim 2 (original). Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride, a hydrate thereof, or mixtures thereof, having an X-ray diffraction pattern which comprises the following peaks: 6.8 ± 0.1 , 10.9 ± 0.1 , 14.2 ± 0.1 and $16.6 \pm 0.1^\circ$ in 2θ ; when the pattern is obtained from a copper radiation source ($\text{CuK}\alpha$; $\lambda = 1.54056 \text{ \AA}$).

Claims 3-14 (cancelled)

Claim 15 (previously presented). A pharmaceutical composition comprising a salt of claim 2 and a pharmaceutical carrier.

Claim 16 (cancelled)

Claim 17 (previously presented). A method of treating non-Hodgkins lymphoma which comprises administering to a mammal in need thereof an effective amount of a compound of claim 2.

Claim 18 (cancelled)

Claim 19 (previously presented). A method of treating glioblastoma which comprises administering to a mammal in need thereof an effective amount of a compound of claim 2.

Claim 20 (cancelled).

Claim 21 (previously presented). A method of treating non-small cell lung cancer which comprises administering to a mammal in need thereof an effective amount of a compound of claim 2.

Claim 22 (cancelled).